Amicus Therapeutics, Inc. (FOLD) Stock Rating Upgraded by BidaskClub
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday.
A number of other research firms have also weighed in on FOLD. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Robert W. Baird increased their price target on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, July 12th. ValuEngine raised shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Bank of America Corporation decreased their price target on shares of Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, May 25th. Finally, Cowen and Company reissued a “buy” rating and set a $16.00 price target (up from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Amicus Therapeutics has a consensus rating of “Buy” and a consensus price target of $14.58.
Shares of Amicus Therapeutics (NASDAQ FOLD) traded up 1.79% during midday trading on Thursday, reaching $12.51. 3,424,906 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $12.55 and its 200-day moving average is $8.75. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $14.05. The stock’s market cap is $2.06 billion.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.03. The firm had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the prior year, the business posted ($0.40) earnings per share. On average, equities analysts expect that Amicus Therapeutics will post ($1.38) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Stock Rating Upgraded by BidaskClub” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/20/amicus-therapeutics-inc-fold-stock-rating-upgraded-by-bidaskclub.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The shares were bought at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jay Barth sold 30,000 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $10.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now owns 64,184 shares in the company, valued at approximately $641,840. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the company. Teacher Retirement System of Texas boosted its stake in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 169 shares during the last quarter. Princeton Alpha Management LP purchased a new stake in shares of Amicus Therapeutics during the first quarter worth approximately $106,000. DORCHESTER WEALTH MANAGEMENT Co purchased a new stake in shares of Amicus Therapeutics during the second quarter worth approximately $111,000. Creative Planning boosted its stake in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,900 shares during the last quarter. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of Amicus Therapeutics during the second quarter worth approximately $124,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.